Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases

Abstract
A phase 3 trial was conducted to evaluate the efficacy of a prophylactic quadrivalent vaccine in preventing anogenital diseases associated with human papillomavirus (HPV) types 6, 11, 16, and 18.